Companies: 10,795·Total market cap: $144.5T
HLS Therapeutics Inc.

HLS Therapeutics Inc.

HLS.TOTSXHealthcare● Active
$4.40
$-0.07(-1.57%)
Market Cap$137604280
P/E Ratio
52W High$5.765
52W Low$0.001

HLS Therapeutics Inc.(HLS.TO)· 损益表

年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q(经 FMP 聚合)· 可在下方切换周期与 M/B/T 单位。

FMP · HLS.TO · 截至 2026-06-08

财务报表

Revenue · Gross Profit · Net Income
Breakdown2025-122024-122023-122022-122021-12
Revenue
Revenue$56.47M$56.62M$63.07M$61.47M$60.01M
Cost of Revenue$32.46M$9.00M$7.62M$4.98M$3.97M
Gross Profit$24.01M$47.62M$55.45M$56.49M$56.04M
Gross Margin %(computed)42.52%84.11%87.91%91.90%93.38%
Operating Expenses
R&D Expenses$0.00M$0.00M$0.00M$0.00M$0.00M
G&A Expenses$10.61M$10.20M$8.39M$17.73M$17.40M
Total Operating Expenses$28.19M$55.31M$55.45M$69.98M$62.32M
Operating Income($4.18M)($7.69M)($10.35M)($13.44M)($6.24M)
Operating Margin %(computed)-7.40%-13.57%-16.41%-21.87%-10.40%
Interest Income$0.11M$0.32M$0.35M$0.06M$0.04M
Interest Expense$7.22M$10.08M$8.75M$7.32M$6.96M
Income Before Tax($13.10M)($15.58M)($27.80M)($23.72M)($11.81M)
Income Tax Expense($0.45M)$4.07M($0.27M)($0.12M)$1.31M
Net Income($12.65M)($19.66M)($27.53M)($23.60M)($13.12M)
Net Margin %(computed)-22.40%-34.71%-43.65%-38.39%-21.86%
Per Share & EBITDA
EPS (Basic)$-0.40$-0.62$-0.85$-0.73$-0.41
Wtd Avg Shares31.53M31.84M32.26M32.33M32.18M
EBITDA$18.02M$17.22M$12.88M$18.00M$25.41M
EBITDA Margin %(computed)31.91%30.41%20.43%29.28%42.35%

数据来源:Financial Modeling Prep · 最后更新:2026-06-08 · USD · M

深入了解HLS Therapeutics Inc.

关于HLS Therapeutics Inc.(HLS.TO)损益表

HLS Therapeutics Inc.(HLS.TO)损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年,HLS.TO实现营收$0.06B,毛利润$0.02B(毛利率42.52%),净利润($0.01B)(净利率-22.40%)。

常见问题

HLS.TO · 4 问

HLS Therapeutics Inc.(HLS.TO)2025财年营收为$0.06B,同比down0.3%。

HLS.TO revenueHLS.TO salesannual revenue YoYincome statement

· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08